Abbott Laboratories (ABT) Other financing activities (2009 - 2026)

Abbott Laboratories has reported Other financing activities for 18 years, with the latest figure at $3.0 million in Q2 2026.

• Quarterly Other financing activities fell 91.43% year-over-year to $3.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $193.0 million (down 56.04% YoY) and the FY2025 annual result came in at $396.0 million, up 50.0% from the prior year.
• Other financing activities declined to $3.0 million in Q2 2026 per ABT's latest filing, from $116.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $287.0 million in Q1 2025 and troughed at $3.0 million in Q2 2026.
• A 5-year average of $61.8 million and a median of $48.5 million in 2022 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2025 and 2026: Other financing activities surged 169.23% in 2025, then plunged 91.43% in 2026.
• Over 5 years, Other financing activities stood at $41.0 million in 2022, then slipped by 17.07% to $34.0 million in 2023, then decreased by 26.47% to $25.0 million in 2024, then tumbled by 80.0% to $5.0 million in 2025, then sank by 40.0% to $3.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $3.0 million, $116.0 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.